3,457 Shares in Loxo Oncology, Inc. (LOXO) Acquired by Jasper Ridge Partners L.P.

Jasper Ridge Partners L.P. acquired a new stake in shares of Loxo Oncology, Inc. (NASDAQ:LOXO) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 3,457 shares of the biopharmaceutical company’s stock, valued at approximately $277,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Legal & General Group Plc grew its holdings in Loxo Oncology by 8.4% during the first quarter. Legal & General Group Plc now owns 3,682 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 284 shares in the last quarter. Wells Fargo & Company MN grew its holdings in Loxo Oncology by 3.8% during the second quarter. Wells Fargo & Company MN now owns 16,095 shares of the biopharmaceutical company’s stock worth $1,291,000 after buying an additional 592 shares in the last quarter. Teachers Advisors LLC grew its holdings in Loxo Oncology by 4.3% during the fourth quarter. Teachers Advisors LLC now owns 22,139 shares of the biopharmaceutical company’s stock worth $711,000 after buying an additional 905 shares in the last quarter. Alps Advisors Inc. grew its holdings in Loxo Oncology by 7.4% during the second quarter. Alps Advisors Inc. now owns 23,601 shares of the biopharmaceutical company’s stock worth $1,893,000 after buying an additional 1,623 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in Loxo Oncology by 4.9% during the first quarter. Goldman Sachs Group Inc. now owns 44,178 shares of the biopharmaceutical company’s stock worth $1,860,000 after buying an additional 2,045 shares in the last quarter.

In other news, insider Naarden Jacob Van sold 1,541 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $73.73, for a total transaction of $113,617.93. Following the transaction, the insider now owns 1,541 shares of the company’s stock, valued at $113,617.93. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Joshua H. Bilenker sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $73.56, for a total value of $1,103,400.00. Following the transaction, the chief executive officer now directly owns 196,207 shares in the company, valued at approximately $14,432,986.92. The disclosure for this sale can be found here. Insiders have sold 46,073 shares of company stock worth $3,397,662 over the last three months. 27.80% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: This piece of content was first posted by Markets Daily and is the property of of Markets Daily. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/09/12/3457-shares-in-loxo-oncology-inc-loxo-acquired-by-jasper-ridge-partners-l-p.html.

Shares of Loxo Oncology, Inc. (LOXO) traded down 0.47% during trading on Tuesday, reaching $75.98. The company’s stock had a trading volume of 89,875 shares. The company has a 50 day moving average of $74.85 and a 200 day moving average of $60.08. The company’s market cap is $2.27 billion. Loxo Oncology, Inc. has a 12-month low of $17.14 and a 12-month high of $84.46.

Loxo Oncology (NASDAQ:LOXO) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.99) by ($0.15). During the same period in the prior year, the company earned ($0.77) earnings per share. On average, analysts anticipate that Loxo Oncology, Inc. will post ($4.54) EPS for the current fiscal year.

Several brokerages recently issued reports on LOXO. Morgan Stanley reiterated an “overweight” rating and set a $91.00 price target on shares of Loxo Oncology in a report on Monday, June 19th. BidaskClub raised Loxo Oncology from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th. Zacks Investment Research raised Loxo Oncology from a “hold” rating to a “buy” rating and set a $82.00 price objective on the stock in a research report on Wednesday, August 9th. Stifel Nicolaus reissued a “buy” rating and issued a $94.00 price objective (up previously from $71.00) on shares of Loxo Oncology in a research report on Thursday, August 10th. Finally, BTIG Research reissued a “buy” rating and issued a $75.00 price objective on shares of Loxo Oncology in a research report on Thursday, August 3rd. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Loxo Oncology currently has a consensus rating of “Buy” and a consensus target price of $70.73.

Loxo Oncology Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Want to see what other hedge funds are holding LOXO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Loxo Oncology, Inc. (NASDAQ:LOXO).

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply